ULTIO Stock Overview
Ultimovacs ASA, empresa biotecnológica, desarrolla inmunoterapias contra el cáncer.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Ultimovacs ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr8.20 |
| 52 Week High | kr109.00 |
| 52 Week Low | kr100.20 |
| Beta | 1.01 |
| 1 Month Change | -93.38% |
| 3 Month Change | -93.67% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -88.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| ULTIO | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 3.0% | -1.1% | -0.5% |
| 1Y | n/a | -29.8% | 0.4% |
Rentabilidad frente al sector: Datos insuficientes para determinar los resultados de ULTIO en comparación con el sector UK Biotechs .
Rentabilidad vs. Mercado: Datos insuficientes para determinar el rendimiento de ULTIO frente al mercado UK.
Price Volatility
| ULTIO volatility | |
|---|---|
| ULTIO Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Precio estable de las acciones: ULTIOha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de ULTIO en el último año.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 26 | Carlos de Sousa | https://ultimovacs.com |
Ultimovacs ASA, empresa biotecnológica, desarrolla inmunoterapias contra el cáncer. Su principal producto candidato es UV1, una vacuna contra el cáncer basada en un péptido que induce una respuesta específica de las células T contra el antígeno universal del cáncer, la telomerasa. La empresa se constituyó en 2011 y tiene su sede en Oslo (Noruega).
Ultimovacs ASA Fundamentals Summary
| ULTIO fundamental statistics | |
|---|---|
| Market cap | kr370.90m |
| Earnings (TTM) | -kr189.24m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.0x
P/E RatioIs ULTIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ULTIO income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr189.24m |
| Earnings | -kr189.24m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | -5.50 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ULTIO perform over the long term?
See historical performance and comparison